Eisai

Eisai, UCL form drug discovery alliance for neurological diseases

Friday, December 14, 2012 10:43 AM

Eisai, a pharmaceutical company based in Toyko, and University College London (UCL) have entered into a new agreement to establish a major drug discovery and development collaboration investigating new ways of treating neurological diseases such as Alzheimer’s disease, Parkinson’s disease and other related disorders.

More... »

Epizyme earns $4M in milestones from GSK for novel HMT therapeutics

Thursday, October 4, 2012 11:52 AM

Epizyme, a pharmaceutical company focused personalized therapeutics for cancer, received a $4 million milestone payments from collaborator GlaxoSmithKline based on the achievement of pre-clinical milestones.

More... »

Eisai partners with PharmaSwiss on chemo agent distribution

Monday, April 9, 2012 02:19 PM

Eisai Europe, the Tokyo-based subsidiary of Eisai, has entered into an agreement with PharmaSwiss, the Switzerland-based division of Valeant Pharmaceuticals International, to promote and distribute the Eisai's novel anticancer agent Halaven (eribulin mesylate) in a number of Central and Eastern European (CEE) countries.

More... »

Eisai resubmits Perampanel NDA to FDA

Tuesday, December 27, 2011 01:28 PM

Eisai has resubmitted the New Drug Application (NDA) for the investigational AMPA-type glutamate receptor antagonist perampanel for partial-onset seizures associated with epilepsy to the FDA. This resubmission comes after the FDA issued a Refusal to File letter in July 2011 in which FDA requested reformatting and reanalyses of some datasets in the dossier. The application was originally submitted in May 2011.

More... »

H3 Biomedicine opens headquarters in Cambridge, Massachusetts

Friday, December 2, 2011 05:10 PM

H3 Biomedicine has opened a new headquarters and 24,000 square feet of state-of-the-art laboratory space in Cambridge, Massachusetts. Over the next year, the company plans to increase its staff to 70 people and further expand into more laboratory space within its building as it continues to pursue its mission to fulfill the promise of personalized cancer medicine.

More... »

Eisai partners with SFJ in new outsourcing model

Friday, September 9, 2011 11:30 AM

Eisai has put the late-stage clinical development, as well as the associated funding, of a candidate compound for thyroid cancer in the hands of SFJ Pharma, wholly subsidiary of a US-based company that specializes in getting innovative drugs to market in Japan, according to PharmaTimes.

More... »

Rejected: Eisai’s Aricept patch

Tuesday, April 26, 2011 01:36 PM

The FDA has rejected Japanese drugmaker Eisai’s patch version of its Alzheimer’s disease drug Aricept (donepezil transdermal system), according to Pharma Times.

More... »

SuperGen and Astex to merge

Friday, April 8, 2011 10:47 AM

U.S.-based SuperGen will merge with the U.K.'s Astex Therapeutics in a deal they say will create "a financially strong international oncology company," according to Pharma Times.

More... »

Eisai expands into Brazil

Friday, April 8, 2011 10:24 AM

Eisai, based in Japan, is moving into Latin America and is opening a subsidiary in Brazil, according to Pharma Times.

More... »

Eisai's eribulin gets EU approval for breast cancer

Tuesday, March 29, 2011 12:44 PM

Regulators in Europe have approved Eisai’s marine-derived breast cancer drug Halaven.

More... »